AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 81 min read$CLGN

CollPlant (NASDAQ: CLGN) gives CFO 510,372 RSUs with 5-year vesting

CollPlant (CLGN) granted its Deputy CEO and CFO, Rotem Eran, 510,372 restricted share units (RSUs) on September 3, 2026. The RSUs vest over five years, with 30% vesting in 2027 and the remainder in equal installments. After a 1-for-10 reverse stock split, Eran's total holdings amount to 516,372 ordinary-share equivalents.

Original reporting
stocktitan.net
Published Sep 8, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLGN
Neutral
medium confidence
Mentioned
$CLGN
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLGNNeutralLow
01

Why it matters

The insider grant adds to existing holdings, modestly increasing insider stake after a reverse split.

02

Market read

Primary disclosure of an insider equity award; limited trading relevance for the broader market.

03

What to watch

Potential future vesting schedule and performance conditions may affect actual impact.

Relevance 4/10Novelty 4/10Timing: post‑grant filing Sep 3 2026

Background

CollPlant Biotechnologies Ltd (NASDAQ: CLGN) filed a Form 4 reporting an insider RSU grant.

Company-level read

Ticker impact

$CLGNNeutralMedium confidence
Context

SEC Form 4 disclosed CFO Rotem Eran received 510,372 RSUs after a 1-for-10 reverse split.

Expected impact

Limited short-term impact; potential slight upside if market views insider alignment positively.

Evidence & confidence

First‑report filing provides new data, but the grant size is not material enough to drive a sizable price move.

Market effects

Sector

Minor signal for biotech staffing and compensation trends.

Regional

No broader regional effect.

Global

Limited to CLGN investors.

Counterpoint

What could challenge this read

The grant could be a dilution risk outweighing any confidence signal.

Key entities

  • Executive
    Rotem Eran

    Deputy CEO and CFO of CollPlant Biotechnologies Ltd.

Read at source← All news

Related articles

SEP 4
$CLGNHighAI 8/10

CollPlant Is Acquiring LightSolver- Enters Supercomputing And Photonic Computing Markets

CollPlant (CLGN) is acquiring LightSolver, a developer of photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address computational speed and energy challenges. The deal includes upfront shares, warrants, and milestone-based payments. LightSolver is working with partners like Boeing (BA) to validate its technology, targeting commercial availability by 2028.

photonicsonline.com2 min
AUG 31
$CLGNHighAI 8/10

COLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS

CollPlant (Nasdaq: CLGN) is acquiring LightSolver, a company developing photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address speed and energy limitations of semiconductor-based computing. The acquisition includes equity and milestone-based warrants. LightSolver is partnering with Boeing (NYSE: BA) and other global leaders for commercial validation. The deal is expected to close this week.

prnewswire.com3 min
MAY 30
$CLGNMedAI 9/10

CollPlant Biotechnologies (NASDAQ:CLGN) Issues Earnings Results

CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly EPS of -$0.23, slightly above analysts’ -$0.24 consensus, according to Zacks. Revenue was $0.07 million versus an expected $0.46 million. The stock opened at $0.40 and was down 0.7%. MarketBeat data shows a $11.50 consensus target and an average “Hold” rating.

dailypolitical.com4 min